References 1 FDABremelanotide (Vyleesi) prescribing information dosing, indication (premenopausal HSDD), and use limitations
Reported incidences in those receiving a 12mg/weekly dose of retatrutide were [21]: Nausea (45% of participants) Vomiting (19%) Constipation (16%) Diarrhea (15%) Cardiac arrhythmia (11%) Fatigue (10%) Increased pancreatic enzyme (lipase) levels (8%) Injection site reactions (8%) Liver issues in 2 participants (3%) Pancreatitis in 1 participant (2%) Both tirzepatide and retatrutide share similar contraindications, including advice against their use during pregnancy and breastfeeding
Masato A, Plotegher N, Terrin F, Sandre M, Faustini G, Thor A, et al
Partners may react with concern, jealousy, or discomfort
Administering your semaglutide injection correctly depends largely on choosing the right injection site and rotating between locations each week